the Image

Clinical Trial Details

If you are a patient or a caregiver and would like to learn more our cancer clinical trials call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials) or email cancerclinicaltrials@bsd.uchicago.edu .

Share this:
Brief Title A Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 in Patients With Advanced Solid Tumours
Official Title A Phase I, Open-Label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of Selumetinib (AZD6244 Hyd-sulfate) in Combination With MEDI4736 in Patients With Advanced Solid Tumours
Principal Investigator Sharma, Manish
Brief Summary This is a phase I, open-label, multi-centre study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumour activity of ascending doses of selumetinib in combination with MEDI4736 in patients with advanced solid tumour
Gender Both
Ages 18 Years
Enrollment 40
Accepts Healthy Volunteers No
Lead Sponsor AstraZenecaIndustry
Collaborator
Study Design Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Study Phase Phase 1
Study Type Interventional
Contact Name
Contact Phone 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials)
Condition Lung Cancer
Detail for Health Professional (on clinicaltrials.gov)
More clinical trials by this PI